How does 6999's PB Ratio compare to its peers?

Insufficient data to calculate 6999's Price-To-Book Ratio vs. peers for valuation analysis.

How does 6999's PB Ratio compare vs other companies in the TW Biotechs Industry?

Insufficient data to calculate 6999's Price-To-Book Ratio vs. industry for valuation analysis.

What is 6999's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 6999's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 6999 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 6999's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Han.biomedical TPEX:6999 Stock Report

Last Price

NT$35.20

Market Cap

NT$668.0m

7D

0.9%

1Y

n/a

Updated

17 Jan, 2025

Data

Company Financials

Han.biomedical Inc.

TPEX:6999 Stock Report

Market Cap: NT$668.0m

6999 Stock Overview

Develops structured biomaterials for tissue regeneration in Taiwan. More details

6999 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (NT$668M)

My Notes

Capture your thoughts, links and company narrative

Han.biomedical Inc. Competitors

Bioray Biotech

TPEX:7561

NT$642.9m

TaiwanJ Pharmaceuticals

TPEX:6549

NT$669.0m

Pharmigene

TPEX:7595

NT$696.4m

Vectorite Biomedical

TPEX:4170

NT$608.4m

Price History & Performance

Summary of share price highs, lows and changes for Han.biomedical
Historical stock prices
Current Share Price	NT$35.20
52 Week High	NT$45.34
52 Week Low	NT$33.41
Beta	0
1 Month Change	-0.85%
3 Month Change	-0.85%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.23%

Recent News & Updates

Recent updates

Shareholder Returns

	6999	TW Biotechs	TW Market
7D	0.9%	-2.8%	0.5%
1Y	n/a	15.0%	28.2%

Return vs Industry: Insufficient data to determine how 6999 performed against the TW Biotechs industry.

Return vs Market: Insufficient data to determine how 6999 performed against the TW Market.

Price Volatility

Is 6999's price volatile compared to industry and market?
6999 volatility
6999 Average Weekly Movement	4.7%
Biotechs Industry Average Movement	4.8%
Market Average Movement	4.5%
10% most volatile stocks in TW Market	7.8%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6999 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: Insufficient data to determine 6999's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	www.hanbiomedical.com

Han biomedical Inc. develops structured biomaterials for tissue regeneration in Taiwan. It offers BarriGel adhesion prevention gel; HANBIO patient lubricant; HANCARE collagen matrix; HANBIO gauze; and LEOFOR hyaluronic acid solution.

Han.biomedical Inc. Fundamentals Summary

How do Han.biomedical's earnings and revenue compare to its market cap?
6999 fundamental statistics
Market cap	NT$668.04m
Earnings (TTM)	NT$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 6999 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6999 income statement (TTM)
Revenue	NT$0
Cost of Revenue	NT$0
Gross Profit	NT$0
Other Expenses	NT$0
Earnings	NT$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 6999 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

n/a

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/17 07:29
End of Day Share Price	2025/01/17 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Han.biomedical Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution